Payment overview · 2025
General Payments
$41.18
2 reported records · 2 companies
Healthcare provider profile · identity verified
Christopher Steven Cosper, MD
Allopathic & Osteopathic Physicians|Family Medicine · GENEVA, AL · NPI 1457312456
Verified facts
What the public records show
CMS Open Payments records show Christopher Steven Cosper, MD received $41.18 in general payments during 2025 across 2 reported records.
PFIZER INC. accounted for 50.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.75 | 50.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.43 | 49.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $41.18 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.75 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
71 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 571 | 90 |
| Alprazolam | Alprazolam | 429 | 66 |
| Lisinopril | Lisinopril | 322 | 79 |
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 90 |
| Meloxicam | Meloxicam | 307 | 90 |
| Gabapentin | Gabapentin | 290 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 280 | 88 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 264 | 72 |
| Tramadol Hcl | Tramadol Hcl | 242 | 49 |
| Losartan Potassium | Losartan Potassium | 238 | 74 |
| Potassium Chloride | Potassium Chloride | 225 | 64 |
| Simvastatin | Simvastatin | 208 | 56 |
| Fluticasone Propionate | Fluticasone Propionate | 195 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 188 | 60 |
| Omeprazole | Omeprazole | 188 | 51 |
| Bupropion Xl | Bupropion Hcl | 187 | 58 |
| Clonazepam | Clonazepam | 186 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 170 | 48 |
| Metformin Hcl Er | Metformin Hcl | 162 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 50 |
| Furosemide | Furosemide | 158 | 44 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 156 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 49 |
| Doxycycline Hyclate | Doxycycline Hyclate | 152 | 102 |
| Ondansetron Odt | Ondansetron | 150 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 41 |
| Temazepam | Temazepam | 145 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 43 |
| Methylprednisolone | Methylprednisolone | 135 | 105 |
| Celecoxib | Celecoxib | 123 | 44 |
| Metformin Hcl | Metformin Hcl | 123 | 30 |
| Ozempic | Semaglutide | 121 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 113 | 29 |
| Mounjaro | Tirzepatide | 108 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 42 |
| Pregabalin | Pregabalin | 107 | 20 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 102 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 100 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 94 | 19 |
| Montelukast Sodium | Montelukast Sodium | 94 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 93 | 26 |
| Januvia | Sitagliptin Phosphate | 92 | 16 |
| Mirtazapine | Mirtazapine | 91 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 24 |
| Xarelto | Rivaroxaban | 87 | 19 |
| Carvedilol | Carvedilol | 85 | 22 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 80 | 57 |
| Allopurinol | Allopurinol | 79 | 24 |
| Azithromycin | Azithromycin | 79 | 52 |
| Baclofen | Baclofen | 79 | 37 |
| Fenofibrate | Fenofibrate | 78 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 22 |
| Glimepiride | Glimepiride | 72 | 23 |
| Methocarbamol | Methocarbamol | 72 | 28 |
| Eliquis | Apixaban | 71 | 13 |
| Levofloxacin | Levofloxacin | 70 | 53 |
| Clonidine Hcl | Clonidine Hcl | 68 | 18 |
| Doxepin Hcl | Doxepin Hcl | 68 | 14 |
| Myrbetriq | Mirabegron | 68 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 68 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 64 | 21 |
| Flurbiprofen | Flurbiprofen | 61 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 61 | 14 |
| Meclizine Hcl | Meclizine Hcl | 60 | 19 |
| Trazodone Hcl | Trazodone Hcl | 58 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 57 | 40 |
| Famotidine | Famotidine | 56 | 25 |
| Linzess | Linaclotide | 52 | 13 |
| Buspirone Hcl | Buspirone Hcl | 50 | suppressed |
| Prednisone | Prednisone | 50 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 11 |
| Promethazine Hcl | Promethazine Hcl | 49 | 17 |
| Valacyclovir | Valacyclovir Hcl | 49 | 19 |
| Mupirocin | Mupirocin | 48 | 39 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 44 | 19 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 44 | 18 |
| Bumetanide | Bumetanide | 43 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 15 |
| Nystatin | Nystatin | 43 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Lovastatin | Lovastatin | 39 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 39 | suppressed |
| Fluconazole | Fluconazole | 38 | 25 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 36 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Atenolol | Atenolol | 33 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 18 |
| Valsartan | Valsartan | 28 | suppressed |
| Letrozole | Letrozole | 27 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Diazepam | Diazepam | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 25 | 18 |
| Cephalexin | Cephalexin | 24 | 19 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Famciclovir | Famciclovir | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 15 |
| Ramipril | Ramipril | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 12 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog | Insulin Lispro | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Invokana | Canagliflozin | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Degludec | Insulin Degludec | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41.18 · 2 records | PFIZER INC. | FARXIGA, VYNDAQEL | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error